Today, the President Myriad RBM, Inc. of Myriad Genetics (MYGN), Ralph Mcdade, sold shares of MYGN for $61.23K.
Following Ralph Mcdade’s last MYGN Sell transaction on August 15, 2016, the stock climbed by 8.6%.
See today’s analyst top recommended stocks >>
Based on Myriad Genetics’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $217 million and quarterly net profit of $2.6 million. In comparison, last year the company earned revenue of $194 million and had a net profit of $32.1 million. MYGN’s market cap is $2.19B and the company has a P/E ratio of 87.51. Currently, Myriad Genetics has an average volume of 1.19M.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $32.50, reflecting a 1.9% upside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through Diagnostics and Other segments. The Diagnostics segment engages in the provision of testing and collaborative development of testing that is designed to asses a risk of developing a disease later in life of an individual.
